NCT06766058 Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy.
| NCT ID | NCT06766058 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Centre, Singapore |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-10-22 |
| Primary Completion | 2027-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2024-10-22 with a primary completion date of 2027-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
ASTER is a multi-part study that aims to prospectively establish evidence for the implementation of aromatherapy as complementary therapy within cancer care in the Singapore context. ASTER 2 study evaluates how extracts from Asian aromatic plants with familiar aromas introduced as inhalation therapy can alleviate distress in breast cancer patients scheduled to undergo radiotherapy (RT).
Eligibility Criteria
Inclusion Criteria: 1. Aged 21 years old and above 2. Confirmed diagnosis of breast cancer of any stage 3. Scheduled to undergo radiotherapy for the first time 4. Capable of providing informed consent Exclusion Criteria: 1. Physically or mentally incapable of providing verbal/written consent 2. Known or suspected hypersensitivity/allergy to essential oils or any components of the formulations 3. Airway hypersensitivity to fragrances, paint fumes or turpentine 4. Taking medications for anxiety (e.g. benzodiazepines) before radiotherapy 5. Pregnant, breastfeeding, or intending to conceive during study period
Contact & Investigator
Dr. Fuh-Yong Wong, MBBS, FRCR
PRINCIPAL INVESTIGATOR
National Cancer Centre, Singapore
Frequently Asked Questions
Who can join the NCT06766058 clinical trial?
This trial is open to female participants only, aged 21 Years or older, up to 99 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06766058 currently recruiting?
Yes, NCT06766058 is actively recruiting participants. Contact the research team at wong.fuh.yong@singhealth.com.sg for enrollment information.
Where is the NCT06766058 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT06766058 clinical trial?
NCT06766058 is sponsored by National Cancer Centre, Singapore. The principal investigator is Dr. Fuh-Yong Wong, MBBS, FRCR at National Cancer Centre, Singapore. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.